Table 1.
Patient baseline demographics and clinical characteristics in those who did/did not meet the four-component definition of clinical remission following 1 year of mepolizumab treatment.
| Four-component clinical remission definition* | ||
|---|---|---|
| Patients who achieved clinical remission (n=43) | Patients who did not achieve clinical remission (n=101) | |
| Age, mean (SD), years | 58.1 (9.06) | 58.8 (14.17) |
| Age at asthma diagnosis, mean (SD), years | n=43; 32.2 (16.62) | n=99; 34.3 (18.99) |
| Female, n (%) | 35 (81) | 73 (72) |
| Ethnicity, n (%) | ||
| Caucasian | 39 (91) | 93 (92) |
| Hispanic | 4 (9) | 6 (6) |
| African | 0 | 2 (2) |
| Other | 0 | 0 |
| BMI, mean (SD), kg/m2 | n=42; 29.0 (5.15) | n=101; 27.8 (5.19) |
| BMI category, n (%), kg/m2 | n=42 | n=101 |
| <18.5 | 0 | 1 (<1) |
| 18.5–<25.0 | 11 (26) | 28 (28) |
| 25.0–<30.0 | 14 (33) | 46 (46) |
| 30.0–<35.0 | 13 (31) | 17 (17) |
| ≥35.0 | 4 (10) | 9 (9) |
| Smoking status, n (%) | ||
| Never | 26 (60) | 60 (59) |
| Ex-smoker (>6 months) | 16 (37) | 39 (39) |
| Current smoker | 0 | 0 |
| Passive smoker | 1 (2) | 1 (<1) |
| Not available | 0 | 1 (<1) |
| Exacerbations in the 12 months pre-mepolizumab treatment, mean (SD) | 4.1 (3.25) | 4.2 (3.10) |
| Baseline blood eosinophil count, † geometric mean (SD log), cells/µL | 653.85 (0.546) | 504.22 (0.779) |
| Baseline blood eosinophil count category,† n (%), cells/µL | ||
| <150 | 1 (2) | 7 (7) |
| 150–<300 | 3 (7) | 9 (9) |
| 300–<500 | 5 (12) | 25 (25) |
| 500–<700 | 10 (23) | 23 (23) |
| ≥700 | 24 (56) | 37 (37) |
| Allergic asthma, n (%) | 25 (58) | 51 (50) |
| Atopic sensitization, n (%) | n=43; 14 (33) | n=101; 43 (43) |
| Baseline ACT score, mean (SD) | n=41; 15.9 (4.88) | n=95; 13.7 (4.99) |
| Baseline ACT score category, n (%) | n=41 | n=95 |
| <20 (uncontrolled) | 31 (76) | 84 (88) |
| ≥20 (controlled) | 10 (24) | 11 (12) |
| Baseline post-bronchodilator FEV1%pred, mean (SD) | n=41 86.9 (21.52) |
n=88 71.2 (23.39) |
| OCS dependent in the 12 months pre-mepolizumab treatment, n (%) | 7 (16) | 53 (52) |
| Baseline OCS dose, median (IQR), mg/day | n=3; 6.3 (5.0, 15.0) | n=42; 10.0 (5.0, 15.0) |
| Previous omalizumab treatment, n (%) | n=43; 11 (26) | n=101; 41 (41) |
| Comorbidities, n (%) | ||
| Anxiety | 12 (28) | 21 (21) |
| Atopic dermatitis | 0 | 2 (2) |
| Bronchiectasis | 10 (23) | 26 (26) |
| Depression | 5 (12) | 24 (24) |
| EGPA | 1 (2) | 5 (5) |
| GERD | 9 (21) | 26 (26) |
| Hypersensitivity to NSAIDs | 8 (19) | 11 (11) |
| CRSwNP | 20 (47) | 44 (44) |
*Definition of clinical remission: exacerbation-free for 52 weeks, OCS-free at Week 52, ACT score ≥20 at Week 52, and predicted post-bronchodilator FEV1 ≥80% at Week 52. 174 patients were excluded owing to missing post-bronchodilator FEV1 values or ACT scores at Week 52. †Where a blood eosinophil count of zero was recorded, a small value (i.e., minimum all non-missing results/2) was added prior to log transformation. ACT, asthma control test; BMI, body mass index; CRSwNP, chronic rhinosinusitis with nasal polyps; EGPA, eosinophilic granulomatosis with polyangiitis; FEV1, forced expiratory volume in 1 second; GERD, gastroesophageal reflux disease; IQR, interquartile range; NSAID, non-steroidal anti-inflammatory drug; OCS, oral corticosteroid; pred, predicted; SD, standard deviation.